Currently known biomarkers of response to anti‐PD-1/PD-L1 therapies include: PD-L1 expression [17, 18], tumor mutational load [19, 20], DNA mismatch repair (MMR) deficiency [21] and CD8+ T-cell intensity [22, 23]. The gene discussed is PDCD1; the disease is neoplasm.